VEGFA and diabetes mellitus: Patients with postoperative ME and DM were most likely to be treated with a DEX implant (57.1%, 4/7), anti-VEGF IT (14.3%, 1/7) or a combined treatment with both a DEX implant and anti-VEGF IT (14.3%).